- $8.72bn
- $8.22bn
- $108.78m
U.S. STOCKS ON THE MOVE-CVS Health, Match Group, Western Union
U.S. STOCKS ON THE MOVE-Lumen Technologies, Estee Lauder, ImmunoGen
Brief: Elahere Demonstrates Overall Survival Benefit In The Phase 3 Mirasol Trial In Patients With FRα-Positive Platinum-Resistant Ovarian Cancer
ImmunoGen surges as ovarian cancer drug succeeds in late-stage study
U.S. RESEARCH ROUNDUP-Chegg, Humana, Paratek Pharmaceuticals
U.S. STOCKS ON THE MOVE-First Republic, Charter Communications, FirstEnergy
ImmunoGen Inc reports results for the quarter ended in March - Earnings Summary
ImmunoGen rises on Q1 revenue beat
Brief: ImmunoGen Reports First Quarter 2023 Financial Results
ImmunoGen Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: ImmunoGen Appoints Isabel Kalofonos As Chief Commercial Officer
Brief: Immunogen Announces Non-Dilutive Term Loan Financing For Up To $175 Mln With Pharmakon Advisors
U.S. STOCKS ON THE MOVE-First Solar, Iveric Bio, Salesforce
ImmunoGen Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Wendy's, HP, Sanofi
ImmunoGen Inc rises on research agreement with Vertex
Brief: Immunogen Reports Recent Progress And 2022 Financial Results
Brief: Immunogen Announces A Global, Multi-Target License And Option Agreement With Vertex For Immunogen's Adc Technology In The Development Of Novel Targeted Conditioning Agents
Brief: ImmunoGen Reports Fourth Quarter EPS of USD -0.23